Next-Generation Envenoming Therapies: From Small Molecules to Antibodies
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Animal Venoms".
Deadline for manuscript submissions: closed (20 July 2023) | Viewed by 418
Special Issue Editors
Interests: antibody discovery; in vitro assays of cytotoxicity and enzyme activity; protein production; in vivo preclinical assays; drug target identification; immunoassays; development of novel diagnostics
Interests: molecular evolution of venom components; venom composition; toxin convergence; venom gland transcriptomics; antivenom manufacturing and testing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antivenom remains the gold-standard treatment for envenoming by snakes, scorpions, spiders and other venomous animals, yet remains largely unchanged since its first development in the 19th Century. Current antivenoms using animal-derived immunoglobulins are associated with numerous deficiencies as a result of this manufacturing practice, including poor efficacy, high manufacturing and treatment cost, high incidence of adverse reactions, and poor thermostability. Current strategies under investigation to improve the treatment of envenoming include the development of human/ised monoclonal antibodies (or cocktails thereof), rational immunogen design to enhance animal-derived antivenoms, and small molecule drugs, to name a few.
The focus of this Special Issue of Toxins will be the development of next-generation envenoming therapies, spanning the breadth of current research from small molecules to immunoglobulins. We encourage original research and review articles that exemplify current research activities in next-generation treatments for envenoming by any venomous animal.
Dr. Stefanie Menzies
Prof. Dr. Nicholas R. Casewell
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antivenom
- therapeutics
- envenoming
- next-generation
- immunogens
- venom
